Authorization

Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

UTRECHT, The Netherlands and BOSTON, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (a??Merusa??, a??wea??, a??oura?? or the a??Companya??), a clinical-stage bispecific antibody company developing BiclonicsA®, innovative full-length human bispecific antibody therapeutics, today announced that data from its MCLA-128 and MCLA-129 programs will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 26-30, 2019 in Boston, Massachusetts.A 
Presentation and Poster Details:A  MCLA-128Presentation
Title: Clinical proof-of-concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
Authors:A  Alison M Schram, Eileen M O'Reilly, Romel Somwar, Ryma Benayed, Sara Shameem, Thrusha Chauhan, Jean Torrisi, Jim Ford,
David Maussang, Ernesto Wasserman, Marc Ladanyi, David M Hyman, L Andres Sirulnik, Alexander E Drilon
Session: Spotlight on Proffered Papers 1
Location: Level 3 - Ballroom AB
Date and Time: Sunday, October 27, 2019 at 11:50 AMPoster
Title: Clinical proof-of-concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
Authors:A  Alison M Schram, Eileen M O'Reilly, Romel Somwar, Ryma Benayed, Sara Shameem, Thrusha Chauhan, Jean Torrisi, Jim Ford,
David Maussang, Ernesto Wasserman, Marc Ladanyi, David M Hyman, L Andres Sirulnik, Alexander E Drilon
Session: Late-Breaking Poster Session B: Monoclonal Antibodies
Location:A  Hall D, Hynes Convention Center, Board Number: 160
Date and Time: Monday, October 28, 2019 from 12:30 PM a?? 4:00 PM EST
Permanent Abstract Number: LB-B12
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »
ПнВтСрЧтПтСбВс
 123456
78910111213
14151617181920
21222324252627
282930